Amy Thompson
11 Papers
1 Citations
Amy Thompson is an academic researcher. The author has contributed to research in topics: Medicine & Implantable cardioverter-defibrillator. The author has an hindex of 3, co-authored 5 publications.
Chat about Author
Papers
Therapy From a Novel Substernal Lead: The ASD2 Study
Lucas V.A. Boersma,Béla Merkely,Petr Neuzil,Ian Crozier,Devender Akula,Liesbeth Timmers,Zbigniew Kalarus,Lou Sherfesee,Paul J. Degroot,Amy Thompson,Daniel R. Lexcen,Bradley P. Knight +11 more
TL;DR: The ASD2 study demonstrated the ability to pace, sense, and defibrillate using a lead designed specifically for the substernal space.
45
Efficacy and Safety of an Extravascular Implantable Cardioverter-Defibrillator.
Paul A. Friedman,Francis Murgatroyd,Lucas V.A. Boersma,Jaimie Manlucu,David O'Donnell,Bradley P. Knight,Nicolas Clementy,Christophe Leclercq,Anish Amin,Béla P Merkely,Ulrika Birgersdotter-Green,Joseph Y S Chan,Mauro Biffi,Reinoud E. Knops,Gregg Engel,Ignacio Muñoz Carvajal,Laurence M. Epstein,Venkata Sagi,Jens Brock Johansen,Maciej Sterliński,Clemens Steinwender,Troy R. Hounshell,Richard Abben,Amy Thompson,Christopher Wiggenhorn,Sarah Willey,Ian Crozier +26 more
TL;DR: It is found that extravascular ICDs were implanted safely and were able to detect and terminate induced ventricular arrhythmias at the time of implantation.
43
The extravascular implantable cardioverter-defibrillator: The pivotal study plan.
Ian Crozier,David O'Donnell,Lucas V.A. Boersma,Francis Murgatroyd,Jaimie Manlucu,Bradley P. Knight,Ulrika Birgersdotter-Green,Christophe Leclercq,Amy Thompson,Robert T. Sawchuk,Sarah Willey,Christopher Wiggenhorn,Paul A. Friedman +12 more
TL;DR: The safety endpoint is freedom from major complications, while the efficacy endpoint is defibrillation success, both endpoints will be assessed against prespecified criteria.
30
9-07: Feasibility of Extravascular Pacing with a Novel Substernal Electrode Configuration: Results from the Multi-center Substernal Pacing Acute Clinical Evaluation (SPACE) Trial
Darius Sholevar,Stanley Tung,Vikas Kuriachan,Peter Leong-Sit,Henri Roukoz,Gregory Engel,Steven P. Kutalek,Devender Akula,Melissa G.T. Christie,Marina Ostanniy,Amy Thompson,Franck Molin +11 more
1
Three-year chronic follow-up from the pilot study of a substernal extravascular implantable cardioverter defibrillator
Ian Crozier,Haris M. Haqqani,E. Kotschet,David Shaw,A Sathia Prabhu,Jochem Jan Roubos,Jeffrey F. Alison,Iain Melton,Russell A. Denman,Tina Lin,A. Almeida,Amy Thompson,Jagdish Lande,Samuel Liang,David O'Donnell +14 more
- 18 May 2022
TL;DR: Lead position and chronic system performance have generally remained stable through 3 years with a low rate of adverse events, and the EV ICD is a novel platform for delivering high-voltage therapy.
1